Navidea Biopharmaceuticals Inc IPO év
Mi az Navidea Biopharmaceuticals Inc IPO év?
A IPO év az Navidea Biopharmaceuticals Inc - 1992
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NYSEMKT-on cégekben a Navidea Biopharmaceuticals Inc -hoz képest
Mit csinál Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
ipo év -hoz hasonló cégek Navidea Biopharmaceuticals Inc
- International Paper APPM nak IPO év 1991 van
- HomeServe Plc nak IPO év 1991 van
- PS Business Parks nak IPO év 1991 van
- Nuveen Michigan Quality Municipal Income Fund nak IPO év 1991 van
- Nuveen Ohio Quality Municipal Income Fund nak IPO év 1991 van
- Tivity Health Inc nak IPO év 1991 van
- Navidea Biopharmaceuticals Inc nak IPO év 1992 van
- ParkerVision nak IPO év 1993 van
- Host Hotels & Resorts Inc nak IPO év 1993 van
- Barrett Business Services nak IPO év 1993 van
- Rocky Brands, Inc nak IPO év 1993 van
- Titan International nak IPO év 1993 van
- Regency Centers nak IPO év 1993 van